Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
8.
Dermatol Ther ; 35(7): e15524, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1956743

ABSTRACT

Recent knowledge on the key role of interleukin (IL) 23/17 axis in psoriasis pathogenesis, led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody specifically targeting IL23. Its efficacy and safety were showed by both clinical trials and real-life experiences. However, real-life data on effectiveness and safety of risankizumab in patients who previously failed anti-IL17 are scant. To assess the efficacy and safety of risankizumab in patients who previously failed anti-IL17. A 52-week real-life retrospective study was performed to assess the long-term efficacy and safety of risankizumab in patients who previously failed anti-IL17. A total of 39 patients (26 male, 66.7%; mean age 50.5 ± 13.7 years) were enrolled. A statistically significant reduction of psoriasis area severity index (PASI) and body surface area (BSA) was assessed at each follow-up (PASI at baseline vs. week 52: 13.7 ± 5.8 vs. 0.9 ± 0.8, p < 0.0001; BSA 21.9 ± 14.6 vs. 1.9 ± 1.7, p < 0.0001). Nail psoriasis severity index improved as well, being statistically significative only at week 16 and thereafter [9.3 ± 4.7 at baseline, 4.1 ± 2.4 (p < 0.01) at week 16, 1.4 ± 0.8 (p < 0.0001) at week 52]. Treatment was discontinued for primary and secondary inefficacy in 1(2.6%) and 3(7.7%) patients, respectively. No cases of serious adverse events were assessed. Our real-life study confirmed the efficacy and safety of risankizumab, suggesting it as a valuable therapeutic weapon among the armamentarium of biologics, also in psoriasis patients who previously failed anti-IL17 treatments.


Subject(s)
Antibodies, Monoclonal, Humanized , Psoriasis , Adult , Antibodies, Monoclonal, Humanized/therapeutic use , Female , Humans , Interleukin-23 , Male , Middle Aged , Psoriasis/chemically induced , Psoriasis/diagnosis , Psoriasis/drug therapy , Retrospective Studies , Severity of Illness Index , Treatment Outcome
13.
J Community Health ; 46(4): 786-793, 2021 08.
Article in English | MEDLINE | ID: covidwho-951422

ABSTRACT

In Italy, as well as in almost all countries, the use of masks in public with several other measures has been an important health measure during the ongoing COVID-19 pandemic. The correct use of masks is essential, as a wrong use and disposal may increase the rate of contagious. Herein, we report a descriptive study evaluating the knowledge and use, reuse and disposal of masks in community settings. An anonymous questionnaire called MaSK (Mask uSe and Knowledge) questionnaire was developed and offered to patients referring at our dermatologic outpatient clinic. A total of 2562 full complete patients' questionnaires were considered for the study. Our results showed that awareness and information campaigns aimed at the general population are urgently needed in order to implement a correct use of masks and limit as much as possible the infection rate.


Subject(s)
COVID-19/prevention & control , Dermatology , Masks/standards , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/epidemiology , Disinfection/methods , Equipment Reuse , Female , Health Knowledge, Attitudes, Practice , Humans , Male , Middle Aged , N95 Respirators , Pandemics , SARS-CoV-2 , Safety Management/organization & administration , Ventilators, Mechanical , Young Adult
14.
J Dermatolog Treat ; : 1-2, 2020 Oct 12.
Article in English | MEDLINE | ID: covidwho-713793

ABSTRACT

The COVID-19 era represented an important stressful event affecting population in many different ways, with important negative impact on social, working and relational life. Indeed, the home-isolation in addition to the high-level of distress given by fear of infection, has significantly resulted in a large number of psychological-consequences. Moreover, in order to guarantee a continuity of care, different measures have been applied among hospitals such as the implementation of teledermatology services. For these reasons, we implemented at our Dermatological-Clinic psychological video-consultations through our teledermatology-services. Herein we report our experience of 23 psychological-video-consultations, which led to achieve a significant reduction of DLQI (from 4.4 ± 3.9 at baseline to 1.6 ± 2.5 at week-4) in patients suffering from chronic skin conditions during the COVID-19 era.

16.
Med Hypotheses ; 143: 109853, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-306036

ABSTRACT

The emergence of the novel betaCoronavirus has raised serious concerns due to the virus rapid dissemination worldwide. Many areas throughout the world are now experiencing the COVID 19 outbreaks with government and policy authorities taking many aggressive isolation or restriction measures, drastically reducing also patient's visits and limiting only to the most urgent ones such as oncological visits or emergencies. Several studies have demonstrated a relationship between increased weight, obesity, diabetes, hypertension and inflammatory skin diseases. Furthermore, weight loss interventions have been shown to improve psoriasis, as well as hidradenitis suppurativa, and increase responsiveness to treatment of this conditions. We suppose that due to aggressive isolation or restriction measures, in the next future dermatologist will face with a common worsening of chronic skin inflammatory conditions due to reduced physical activities, increased intake of calories with the derived increase body weight and always more frequent treatment discontinuation. It is time to start potential preventive strategies which could limit the expected negative impact of COVID-19 related quarantine on skin diseases.


Subject(s)
Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Skin Diseases/epidemiology , Skin Diseases/physiopathology , Betacoronavirus , Body Weight , COVID-19 , Dermatology/trends , Disease Outbreaks , Disease Progression , Exercise , Humans , Inflammation , Obesity/complications , Overweight/complications , Pandemics , Quarantine , SARS-CoV-2 , Social Isolation , Weight Gain
SELECTION OF CITATIONS
SEARCH DETAIL